In this episode of the Oncology Brothers podcast, we dived into the exciting world of lung cancer treatments, focusing on the recent FDA approval of Zongertinib, the first oral tyrosine kinase inhibitor (TKI) specifically approved for HER2-positive lung cancer. Dr. Joshua Sabari, who joined us from NYU Langone Cancer Center, shared his insights on this groundbreaking development.
We started by discussing the prevalence of HER2 mutations in non-small cell lung cancer (NSCLC), which occur in about 2-4% of cases. Dr. Sabari clarified the different types of HER2 alterations, including mutations, overexpression, and amplification, and emphasized the importance of accurate testing to match patients with the appropriate therapies.
The conversation then shifted to the Beamion LUNG-1 study, which demonstrated a remarkable 71% response rate in patients with HER2 tyrosine kinase domain mutations treated with Zongertinib. We explored the study's design, findings, and the impressive median progression-free survival of 12.4 months, highlighting the targeted nature of this therapy and its favorable side effect profile compared to other treatments like trastuzumab deruxtecan (T-DXd).
Dr. Sabari provided practical insights on how to approach treatment decisions in the clinic, particularly regarding the sequencing of Zongertinib and T-DXd, and the management of common side effects such as diarrhea and skin reactions. We also touched on the ongoing research regarding CNS metastases and the potential activity of Zongertinib in patients with HER2 overexpression.
As we wrapped up, we recapped the key points discussed, including the significance of Zongertinib's approval and its implications for clinical practice.